Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats

Synapse

Volumn 64, Issue 7, 2010, Pages 533-541

  Ferger, Boris ^a   Buck, Kerstin ^a   Shimasaki, Makoto ^a   Koros, Eliza ^a   Voehringer, Patrizia ^a   Buerger, Erich ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Haloperidol; In vivo microdialysis; Parkinson's disease; Pramipexole; Reserpine; Striatum

Indexed keywords

DOPAMINE; HALOPERIDOL; PRAMIPEXOLE; RESERPINE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG RELEASE; MALE; MICRODIALYSIS; MINIPUMP; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; BENZOTHIAZOLES; CATALEPSY; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; EXTRACELLULAR SPACE; HALOPERIDOL; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SUBCUTANEOUS; MALE; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PHOTOPERIOD; RATS; RATS, WISTAR; RESERPINE; TIME FACTORS;

EID: 77953851442     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20759     Document Type: Article

References (41)

1. Bezard E, Brotchie JM, Gross CE. 2001. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nat Rev Neurosci 2:577-588.
2. Bibbiani F, Costantini LC, Patel R, Chase TN. 2005. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192:73-78.
3. Carter AJ, Muller RE. 1991. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 200:65-72.
4. Chernoloz O, El MM, Blier P. 2009. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 34:651-661.
5. Danzeisen R, Schwalenstoecker B, Gillardon F, Buerger E, Krzykalla V, Klinder K, Schild L, Hengerer B, Ludolph AC, Dorner- Ciossek C, Kussmaul L. 2006. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 316:189-199.
6. De Ryck M, Teitelbaum P. 1983. Morphine versus haloperidol catalepsy in the rat: an electromyographic analysis of postural support mechanisms. Exp Neurol 79:54-76.
7. De Ryck M, Schallert T, Teitelbaum P. 1980. Morphine versus haloperidol catalepsy in the rat: A behavioral analysis of postural support mechanisms. Brain Res 201:143-172.
8. Deleu D, Hanssens Y, Northway MG. 2004. Subcutaneous apomorphine: An evidence-based review of its use in Parkinson's disease. Drugs Aging 21:687-709.
9. Ellenbroek B, Schwarz M, Sontag KH, Cools A. 1985. The importance of the striato-nigro-collicular pathway in the expression of haloperidol-induced tonic electromyographic activity. Neurosci Lett 54:189-194. (Pubitemid 15000376)
10. Ferger B, Teismann P, Mierau J. 2000. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: An in vivo microdialysis study. Brain Res 883:216-223.
11. Fischer DA, Ferger B, Kuschinsky K. 2002. Discrimination of morphine- and haloperidol-induced muscular rigidity and akinesia/catalepsy in simple tests in rats. Behav Brain Res 134:317-321.
12. Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS. 1996. In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol 308:261-269.
13. Hoffman DC, Donovan H. 1995. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 120:128-133.
14. Iravani MM, Sadeghian M, Leung CC, Tel BC, Rose S, Schapira AH, Jenner P. 2008. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol 212:522-531.
15. Jenner P. 2008. Preventing and controlling dyskinesia in Parkinson's disease - A view of current knowledge and future opportunities. Mov Disord 23 (Suppl 3):S585-S598.
16. Kreitzer AC, Malenka RC. 2007. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445:643-647.
17. Kvernmo T, Hartter S, Burger E. 2006. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28:1065-1078.
18. Lorenc-Koci E, Wolfarth S. 1999. Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. Eur J Pharmacol 385:39-46.
19. Lorenc-Koci E, Wolfarth S, Ossowska K. 1996. Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Exp Brain Res 109:268-276. (Pubitemid 26142145)
20. Maj J, Rogoz Z, Skuza G, Kolodziejczyk K. 1997. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol 324:31-37. (Pubitemid 27160905) (Pubitemid 27160905)
21. Maruya H, Watanabe Y, Okita M, Lawlor GF, Utsumi H, Niitsuma T. 2003. Inhibitory effects of D2 agonists by striatal injection on excessive release of dopamine and hyperactivity induced by Bay K 8644 in rats. Neuroscience 118:1091-1098.
22. Mierau J, Schingnitz G. 1992. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 215:161-170.
23. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. 1995. Pramipexole binding and activation of cloned and expressed dopamine D2. D3 and D4 receptors. Eur J Pharmacol 290:29-36.
24. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de PT, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ. 2008. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol 74:1345-1358.
25. Nutt JG, Obeso JA, Stocchi F. 2000. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 23:S109-S115.
26. Nyholm D. 2006. Pharmacokinetic optimisation in the treatment of Parkinson's disease: An update. Clin Pharmacokinet 45:109-136.
27. Okura T, Ito R, Ishiguro N, Tamai I, Deguchi Y. 2007. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci 80:1564-1571.
28. Olanow CW, Obeso JA, Stocchi F. 2006. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2:382-392.
29. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates. San Diego: Academic Press.
30. Piercey MF. 1998. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 21:141-151. (Pubitemid 28248773)
31. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. 1996. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: Comparison to other dopamine receptor agonists. Eur J Pharmacol 312:35-44.
32. Robertson GS, Tham CS, Wilson C, Jakubovic A, Fibiger HC. 1993. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J Pharmacol Exp Ther 264:1344-1351.
33. Sanberg PR, Bunsey MD, Giordano M, Norman AB. 1988. The catalepsy test: Its ups and downs. Behav Neurosci 102:748-759.
34. Schmidt WJ, Bubser M, Hauber W. 1992. Behavioural pharmacology of glutamate in the basal ganglia. J Neural Transm Suppl 38:65-89. (Pubitemid 23026847)
35. Seeman P, Van Tol HH. 1994. Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264-270.
36. Steiger M. 2008. Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: A new treatment paradigm in Parkinson's disease. Eur J Neurol 15:6-15.
37. Stockwell KA, Virley DJ, Perren M, Iravani MM, Jackson MJ, Rose S, Jenner P. 2008. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Exp Neurol 211:172-179.
38. Wolf ME, Roth RH. 1987. Dopamine neurons projecting to the medial prefrontal cortex possess release-modulating autoreceptors. Neuropharmacology 26:1053-1059.
39. Wolf ME, Roth RH. 1990. Autoreceptor regulation of dopamine synthesis. Ann NY Acad Sci 604:323-343.
40. Wright CE, Sisson TL, Ichhpurani AK, Peters GR. 1997. Steadystate pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 37:520-525. (Pubitemid 27265653)
41. Zapata A, Shippenberg TS. 2002. D(3) receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens. J Neurochem 81:1035-1042.